Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Vaccines

Free Subscription 05.08.2019 1 Clin Infect Dis 1 Infect Immun 1 J Infect Dis 2 J Virol 2 Lancet Child Adolesc Health 5 Lancet Infect Dis 1 MMWR Morb Mortal Wkly Rep 2 N Engl J Med 4 PLoS One 1 Proc Natl Acad Sci U S A 2 Science 26 Vaccine

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Clin Infect Dis

1. RAY GT, Lewis N, Klein NP, Daley MF, et al
   Depletion of Susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness.
   Clin Infect Dis. 2019 Jul 28. pii: 5540005. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Infect Immun

2. NARITA K, Hu DL, Asano K, Nakane A, et al
   IL-10 produced by mutant toxic shock syndrome toxin-1 vaccine-induced memory T cells downregulates IL-17 production and abrogates the protective effect against Staphylococcus aureus infection.
   Infect Immun. 2019 Jul 29. pii: IAI.00494-19. doi: 10.1128/IAI.00494.
   PubMed     Text format     Abstract available
   
   

   
   J Infect Dis

3. KURUP D, Fisher CR, Smith TG, Abreu-Mota T, et al
   Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge.
   J Infect Dis. 2019 Aug 3. pii: 5543203. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   J Virol

4. WONG YC, Croft S, Smith SA, Lin LCW, et al
   Vaccinia Virus Strain MVA can Induce Optimal CD8(+) T cell responses to Directly Primed Antigens Depending on Vaccine Design.
   J Virol. 2019 Aug 2. pii: JVI.01154-19. doi: 10.1128/JVI.01154.
   PubMed     Text format     Abstract available
   
   
5. HRYCAK CP, Windmann S, Bayer W
   Comparative evaluation of the vaccine efficacy of three adenovirus-based vector types in the Friend retrovirus infection model.
   J Virol. 2019 Aug 2. pii: JVI.01155-19. doi: 10.1128/JVI.01155.
   PubMed     Text format     Abstract available
   
   

   
   Lancet Child Adolesc Health

6. LI Y, Zhou Y, Cheng Y, Wu P, et al
   Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study.
   Lancet Child Adolesc Health. 2019 Jul 30. pii: S2352-4642(19)30185.
   PubMed     Text format     Abstract available
   
   
7. ZHANG D
   A template for EV-A71 vaccine evaluation in the real world.
   Lancet Child Adolesc Health. 2019 Jul 30. pii: S2352-4642(19)30181.
   PubMed     Text format    
   
   

   
   Lancet Infect Dis

8. CANCADO B, Aranda C, Mallozi M, Weckx L, et al
   Yellow fever vaccine and egg allergy.
   Lancet Infect Dis. 2019;19:812.
   PubMed     Text format    
   
   
9. ZAMAN K, Anand A
   Complex task to estimate immune responses to various poliovirus vaccines and vaccination schedules.
   Lancet Infect Dis. 2019 Jul 23. pii: S1473-3099(19)30322.
   PubMed     Text format    
   
   
10. MACKLIN GR, Grassly NC, Sutter RW, Mach O, et al
    Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
    Lancet Infect Dis. 2019 Jul 23. pii: S1473-3099(19)30301.
    PubMed     Text format     Abstract available
    
    
11. MODJARRAD K, Roberts CC, Mills KT, Castellano AR, et al
    Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
    Lancet Infect Dis. 2019 Jul 24. pii: S1473-3099(19)30266.
    PubMed     Text format     Abstract available
    
    
12. YOON IK, Kim JH
    First clinical trial of a MERS coronavirus DNA vaccine.
    Lancet Infect Dis. 2019 Jul 24. pii: S1473-3099(19)30397.
    PubMed     Text format    
    
    

    
    MMWR Morb Mortal Wkly Rep

13. ADAMU US, Archer WR, Braka F, Damisa E, et al
    Progress Toward Poliomyelitis Eradication - Nigeria, January 2018-May 2019.
    MMWR Morb Mortal Wkly Rep. 2019;68:642-646.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

14. ILUNGA KALENGA O, Moeti M, Sparrow A, Nguyen VK, et al
    The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018-2019.
    N Engl J Med. 2019;381:373-383.
    PubMed     Text format     Abstract available
    
    
15. STREBEL PM, Orenstein WA
    Measles.
    N Engl J Med. 2019;381:349-357.
    PubMed     Text format    
    
    

    
    PLoS One

16. ALESSANDRINI V, Anselem O, Girault A, Mandelbrot L, et al
    Does the availability of influenza vaccine at prenatal care visits and of immediate vaccination improve vaccination coverage of pregnant women?
    PLoS One. 2019;14:e0220705.
    PubMed     Text format     Abstract available
    
    
17. BRICOUT H, Torcel-Pagnon L, Lecomte C, Almas MF, et al
    Determinants of shingles vaccine acceptance in the United Kingdom.
    PLoS One. 2019;14:e0220230.
    PubMed     Text format     Abstract available
    
    
18. ANDRESEN AMS, Lutfi E, Ruyter B, Berge G, et al
    Interaction between dietary fatty acids and genotype on immune response in Atlantic salmon (Salmo salar) after vaccination: A transcriptome study.
    PLoS One. 2019;14:e0219625.
    PubMed     Text format     Abstract available
    
    
19. VAN DER LINDEN M, Imohl M, Perniciaro S
    Limited indirect effects of an infant pneumococcal vaccination program in an aging population.
    PLoS One. 2019;14:e0220453.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. BOOPATHY AV, Mandal A, Kulp DW, Menis S, et al
    Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination.
    Proc Natl Acad Sci U S A. 2019 Jul 29. pii: 1902179116.
    PubMed     Text format     Abstract available
    
    

    
    Science

21. WADMAN M
    Measles epidemic in Ukraine drove troubling European year.
    Science. 2019;363:677-678.
    PubMed     Text format    
    
    
22. CRANK MC, Ruckwardt TJ, Chen M, Morabito KM, et al
    A proof of concept for structure-based vaccine design targeting RSV in humans.
    Science. 2019;365:505-509.
    PubMed     Text format     Abstract available
    
    

    
    Vaccine

23. ESTEBAN-VASALLO MD, Dominguez-Berjon MF, Garcia-Riolobos C, Zoni AC, et al
    Effect of mobile phone text messaging for improving the uptake of influenza vaccination in patients with rare diseases.
    Vaccine. 2019 Jul 25. pii: S0264-410X(19)30970.
    PubMed     Text format     Abstract available
    
    
24. CHEN XX, Wagner AL, Zheng XB, Xie JY, et al
    Hepatitis E vaccine in China: Public health professional perspectives on vaccine promotion and strategies for control.
    Vaccine. 2019 Jul 25. pii: S0264-410X(19)30988.
    PubMed     Text format     Abstract available
    
    
25. YAO PP, Miao ZP, Xu F, Lu HJ, et al
    An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates.
    Vaccine. 2019 Jul 24. pii: S0264-410X(19)30937.
    PubMed     Text format     Abstract available
    
    
26. CHANTLER T, Letley L, Paterson P, Yarwood J, et al
    Optimising informed consent in school-based adolescent vaccination programmes in England: A multiple methods analysis.
    Vaccine. 2019 Jul 24. pii: S0264-410X(19)30969.
    PubMed     Text format     Abstract available
    
    
27. BRANDILEONE MC, Zanella RC, Almeida SCG, Cassiolato AP, et al
    Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil.
    Vaccine. 2019 Jul 24. pii: S0264-410X(19)30934.
    PubMed     Text format     Abstract available
    
    
28. LUCERO MS, Richetta M, Chimeno Zoth S, Jaton J, et al
    Plant-based vaccine candidate against Infectious bursal disease: An alternative to inactivated vaccines for breeder hens.
    Vaccine. 2019 Jul 24. pii: S0264-410X(19)30990.
    PubMed     Text format     Abstract available
    
    
29. REED L, Tarini BA, Andreae MC
    Vaccine administration error rates at a large academic medical center and its affiliated clinics - Familiarity matters.
    Vaccine. 2019 Jul 23. pii: S0264-410X(19)30918.
    PubMed     Text format     Abstract available
    
    
30. HAN B, Wang S, Wan Y, Liu J, et al
    Has the public lost confidence in vaccines because of a vaccine scandal in China.
    Vaccine. 2019 Jul 22. pii: S0264-410X(19)30950.
    PubMed     Text format     Abstract available
    
    
31. CARRYN S, Feyssaguet M, Povey M, Di Paolo E, et al
    Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Vaccine. 2019 Jul 22. pii: S0264-410X(19)30940.
    PubMed     Text format     Abstract available
    
    
32. SPITTELER MA, Romo A, Magi N, Seo MG, et al
    Validation of a high performance liquid chromatography method for quantitation of foot-and-mouth disease virus antigen in vaccines and vaccine manufacturing.
    Vaccine. 2019 Jul 25. pii: S0264-410X(19)30949.
    PubMed     Text format     Abstract available
    
    
33. HADJ MB, Bouguerra H, Saffar F, Chelly S, et al
    Corrigendum to 'Observational study of vaccine effectiveness 20years after the introduction of universal hepatitis B vaccination in Tunisia' [Vaccine 36 (2018) 5858-5864].
    Vaccine. 2019 Jul 25. pii: S0264-410X(19)30321.
    PubMed     Text format    
    
    
34. BARRY E, Cassels F, Riddle M, Walker R, et al
    Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference.
    Vaccine. 2019;37:4768-4774.
    PubMed     Text format     Abstract available
    
    
35. MUNOZ FM, Anderson EJ, Bernstein DI, Harrison CJ, et al
    Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.
    Vaccine. 2019 Jul 30. pii: S0264-410X(19)31006.
    PubMed     Text format     Abstract available
    
    
36. GUIDRY JPD, Carlyle KE, Perrin PB, LaRose JG, et al
    A path model of psychosocial constructs predicting future Zika vaccine uptake intent.
    Vaccine. 2019 Jul 30. pii: S0264-410X(19)30972.
    PubMed     Text format     Abstract available
    
    
37. O'NEILL LM, Keane OM, Ross PJ, Nally JE, et al
    Evaluation of protective and immune responses following vaccination with recombinant MIP and CPAF from Chlamydia abortus as novel vaccines for enzootic abortion of ewes.
    Vaccine. 2019 Jul 30. pii: S0264-410X(19)30879.
    PubMed     Text format     Abstract available
    
    
38. ANDREWS N, Stowe J, Thomas SL, Walker JL, et al
    The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England.
    Vaccine. 2019 Jul 30. pii: S0264-410X(19)30967.
    PubMed     Text format     Abstract available
    
    
39. DALAL J, Rana R, Harale K, Hanif S, et al
    Development and pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Neisseria meningitidis serogroup C.
    Vaccine. 2019 Jul 29. pii: S0264-410X(19)30951.
    PubMed     Text format     Abstract available
    
    
40. KWAK HW, Park HJ, Ko HL, Park H, et al
    Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.
    Vaccine. 2019 Jul 29. pii: S0264-410X(19)30991.
    PubMed     Text format     Abstract available
    
    
41. PERRETT SE, Cottrell S, Shankar AG
    Hepatitis B vaccine coverage in short and long stay prisons in Wales, UK 2013-2017 and the impact of the global vaccine shortage.
    Vaccine. 2019;37:4872-4876.
    PubMed     Text format     Abstract available
    
    
42. BELINGHERI M, De Vito G, Riva MA
    Italian midwives and influenza vaccination: problems in adherence and perception.
    Vaccine. 2019;37:4851.
    PubMed     Text format    
    
    
43. INNIS BL, Scorza FB, Blum JS, Jain VK, et al
    Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations.
    Vaccine. 2019;37:4830-4834.
    PubMed     Text format     Abstract available
    
    
44. INNIS BL, Berlanda Scorza F, Blum JS, Jain VK, et al
    Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity.
    Vaccine. 2019;37:4823-4829.
    PubMed     Text format     Abstract available
    
    
45. WHITE JA, Lal M
    Technical product attributes in development of an oral enteric vaccine for infants.
    Vaccine. 2019;37:4800-4804.
    PubMed     Text format     Abstract available
    
    
46. GIERSING BK, Porter CK, Kotloff K, Neels P, et al
    How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
    Vaccine. 2019;37:4778-4783.
    PubMed     Text format     Abstract available
    
    
47. WIERZBA TF
    Implications and measurement of herd protection (indirect effects) for enteric vaccine development.
    Vaccine. 2019;37:4775-4777.
    PubMed     Text format     Abstract available
    
    
48. CARTER ED, Tam Y, Walker N
    Impact of vaccination delay on deaths averted by pneumococcal conjugate vaccine: Modeled effects in 8 country scenarios.
    Vaccine. 2019 Jul 30. pii: S0264-410X(19)30971.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: